Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Bergamaschini

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|July 10, 2003
[Pulmonary circulation in the history of medicine]Mario Morpurgo, Luigi Bergamaschini
Molecular Immunology|August 14, 2003
Recent advances in the use of C1 inhibitor as a therapeutic agentLuigi Bergamaschini, Marco Cicardi
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|November 24, 2004
[Does a "senile heart" actually exist?]Mario Morpurgo, Luigi Bergamaschini
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|December 2, 2005
[The arterial pulse: from oblivious to revival?]Mario Morpurgo, Luigi Bergamaschini
Medical Oncology (Northwood, London, England)|December 31, 2017
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomasRoberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
European Journal of Ageing|August 12, 2017
Day care centre attendance and quality of life in depressed older adults living in the communityClaudio Bilotta, Luigi Bergamaschini, Sibilla Spreafico, et al.
Anti-Cancer Drugs|February 3, 2021
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatmentsRoberto Castelli, Antonio Gidaro, Giorgio L Deliliers, et al.
Expert Review of Hematology|October 27, 2017
Personalized treatment strategies for elderly patients with myelodysplastic syndromesRoberto Castelli, Luigi Bergamaschini, Riccardo Schiavon, et al.
Archives of Internal Medicine|April 28, 2004
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatmentMarco Cicardi, Lorenza C Zingale, Luigi Bergamaschini, et al.
Thescientificworldjournal|September 8, 2009
Alzheimer's disease: another target for heparin therapyLuigi Bergamaschini, Emanuela Rossi, Carlo Vergani, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|July 10, 2003
[Pulmonary circulation in the history of medicine]Mario Morpurgo, Luigi Bergamaschini
Molecular Immunology|August 14, 2003
Recent advances in the use of C1 inhibitor as a therapeutic agentLuigi Bergamaschini, Marco Cicardi
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|November 24, 2004
[Does a "senile heart" actually exist?]Mario Morpurgo, Luigi Bergamaschini
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|December 2, 2005
[The arterial pulse: from oblivious to revival?]Mario Morpurgo, Luigi Bergamaschini
Medical Oncology (Northwood, London, England)|December 31, 2017
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomasRoberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
European Journal of Ageing|August 12, 2017
Day care centre attendance and quality of life in depressed older adults living in the communityClaudio Bilotta, Luigi Bergamaschini, Sibilla Spreafico, et al.
Anti-Cancer Drugs|February 3, 2021
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatmentsRoberto Castelli, Antonio Gidaro, Giorgio L Deliliers, et al.
Expert Review of Hematology|October 27, 2017
Personalized treatment strategies for elderly patients with myelodysplastic syndromesRoberto Castelli, Luigi Bergamaschini, Riccardo Schiavon, et al.
Archives of Internal Medicine|April 28, 2004
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatmentMarco Cicardi, Lorenza C Zingale, Luigi Bergamaschini, et al.
Thescientificworldjournal|September 8, 2009
Alzheimer's disease: another target for heparin therapyLuigi Bergamaschini, Emanuela Rossi, Carlo Vergani, et al.
Pageof 5